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Abstract
Background: Poor drug quality is a matter of serious concern, especially in countries where drug regulation and
law enforcement are constrained by limited resources. This study was carried out to investigate the cause of quality
failure of omeprazole in Cambodia in 2010 and Myanmar in 2014.
Methods: We conducted pharmacopoeial quantity, content uniformity and dissolution tests of 156 samples of
omeprazole capsules collected in Cambodia in 2010 and Myanmar in 2014. High failure rates were found, especially in
dissolution testing, and detailed investigation of several unacceptable samples was carried out by means of in-vitro
dissolution profiling, scanning electron microscopy (SEM) and X-ray computed tomography (X-ray CT) to identify the
cause of failure.
Results: Dissolution profiling with and without the acid stage showed that acid caused premature omeprazole release,
indicating that the enteric coating of the omeprazole granules was ineffective. SEM examination of two failed samples
revealed cracked and broken granules mixed with apparently intact omeprazole granules in the capsule. X-ray
CT examination indicated that some granules of failed samples completely lacked enteric coating, and others
had incomplete and non-uniform enteric coating or malformation.
Conclusions: Omeprazole capsules collected in Myanmar and Cambodia showed high failure rates in pharmacopoeial
tests, especially dissolution tests. Some samples were found to have ineffective or absent enteric coating of the granules,
resulting in premature dissolution and degradation in acidic conditions. This is a potentially serious public health issue
that needs to be addressed by regulatory authorities in Cambodia and Myanmar, possibly through a collaborative
initiative with manufacturers.
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Background
There is considerable evidence that the incidence of fal-
sified and substandard medicines is increasing, particu-
larly in middle- and lower-income countries [1–3].
There have been many well-established instances of
spurious, falsely labeled, falsified or counterfeit (SFFC)
medicines in recent years [4–10]. In addition, substand-
ard medicines, which are prepared by legitimate manu-
facturers but fail to meet pharmacopoeial requirements,
also constitute an enormous public health problem
[11–15]. On-going surveillance seems essential.
The substituted benzimidazoles are a class of anti-
secretory compounds that suppress gastric acid secretion
by inhibition of the H+/K+-ATPase enzyme system at
the secretory surface of gastric parietal cells [16, 17].
Among them, omeprazole, 5-methoxy-2-[[(4-methoxy-
3,5-dimethyl-2-pyrinylmethyl-sulfinyl)-1H-benzimidazole, is
a basic compound that acts as a proton pump inhibitor,
and is used in the treatment of acid reflux and heartburn
[18]. It is acid-labile, being degraded rapidly in aqueous
solution at low pH [19, 20]. Pre-formulation studies con-
firmed that it is susceptible to moisture, heat and acidic
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solvents [21, 22]. Therefore, to avoid degradation of
omeprazole by acid in the stomach, the drug must be
enteric-coated [23, 24]. Consequently, omeprazole dosage
forms are prepared and marketed in an enteric-coated
form that allows the omeprazole core to be specifically re-
leased and dissolved in the duodenum (pH > 5) or ter-
minal ileum where the pH is about 6.8 to 7.5 [25].
Despite increasing attention to the quality of medi-
cines for communicable diseases, focus on medicines for
non-communicable diseases remains inadequate. In
2010, quality test results of omeprazole in Cambodia in-
dicated that more inspection and monitoring of medi-
cines for non-communicable diseases is necessary [6].
The availability of falsified and substandard medicines in
Myanmar was reported by WHO in 1999 [15], but since
then there has been no systematic survey in the country,
and the current situation is unclear, except for sporadic
reports of falsified medicines. Based on our experience
in Cambodia during 2006-2013 [6], where we encoun-
tered various poor quality (mostly substandard) medi-
cines, omeprazole was chosen as one of the target
medicines for investigation in Myanmar, in consultation
with the Department of Food and Drug Administration
(FDA), Myanmar. Among 156 samples of omeprazole
capsules collected in Cambodia in 2010 and Myanmar in
2014, we found high failure rates in pharmacopoeial
tests, especially dissolution tests. This is broadly consist-
ent with other reports of substandard drugs in
Cambodia [26, 27].
The aim of the present study was to establish the
cause of the high failure rate of omeprazole capsules
from the two countries in dissolution tests by means of
detailed evaluation of the in-vitro dissolution profile, as
well as scanning electron microscopy (SEM) and X-ray
computed tomography (X-ray CT) examinations.
Methods
Materials
United States Pharmacopeia (USP) reference standard
omeprazole was procured from USP Convention. Au-
thentic omeprazole standard capsules (Losec) were
provided by AstraZeneca. Lansoprazole (internal stand-
ard) was from Sigma Aldrich (India). NaH2PO4.2H2O,
Na2HPO4, Na3PO4, KH2PO4 and other chemicals of
reagent grade were purchased from Nacalai Tesque Inc.
(Kyoto, Japan). Distilled water was used for the prepar-
ation of HPLC eluents.
The investigational samples consisted of 154 samples
of hard gelatin capsules containing 20 mg of omeprazole
in enteric-coated pellets and 2 tablet samples purchased
from different drug stores in Cambodia in 2010 and
Myanmar in 2014. In Cambodia, samples were collected
from pharmacies, depots, wholesaler and outlets of
Phnom Penh, Svay Rieng and Kandal provinces. In
Myanmar, collected samples were from pharmacy, hos-
pital, and wholesalers of Yangon region. These samples
of different serial and batch number were imported to
Cambodia and Myanmar from 53 different manufac-
turers in seven countries. Samples were stored below
25 °C after collecting and all the quality analysis of the
samples was finished before the expiration date of the
samples. After quality-testing as required by the indi-
cated pharmacopoeia, we selected five samples for fur-
ther investigation based on the gravity of their failure in
the dissolution test.
HPLC determination of omeprazole
To assess the pharmaceutical quality of the omeprazole
samples, the active ingredient was detected by a simple
reverse phase high performance liquid chromatography
(HPLC). HPLC was run on a Phenomenex Gemini NX
C18 column (150 × 4.6 mm), with a Prominence HPLC
Photo Diode Array Detector (SPD-20A/20AV Series;
Shimadzu, Kyoto, Japan). The temperature of the col-
umn oven was set to 25 °C. Elution buffer was prepared
by dissolving 1.17 g NaH2PO4.2H2O and 1.06 g
Na2HPO4 in 1000 ml of water; the pH was adjusted to
6.8. The column was eluted with a mixture of phosphate
buffer and acetonitrile (60:40) at a flow rate of 0.5 ml/min.
Detection wavelength and injection volume were 302 nm
and 10 μL, respectively for British Pharmacopoeia (BP)
samples. For USP samples, the flow rate was 1 ml/min,
detection wavelength was 280 nm, and injection volume
was 10 μL. The system suitability for the analysis of omep-
razole was verified according to USP 37. The limit of de-
tection (LOD) and limit of quantification (LOQ) of
omeprazole was determined by the slope of the calibration
curve and the standard deviation of responses. For each
linearity solution of 5 different concentrations, average
area of the multiple injections (n = 3) were taken and graph
of concentration in μg/ml (X-axis) versus peak area re-
sponse (Y-axis) was plotted. LOD and LOQ concentrations
of omeprazole were determined on the basis of equation,
Limit of Detection ¼ 3:3 σ=S;
and
Limit of Quantification ¼ 10 σ=S
Where, σ = the standard deviation of the response
S = the slope of the calibration curve
A linear relationship between the peak area and con-
centration of each reference standard was observed
within the range of 25–200% of the active ingredient
(r2 = 0.999–1.000), and the assay was performed within
that range. In addition, the method was validated as
being repeatable and accurate (n = 6).
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Omeprazole quantity and content uniformity tests
Quantity and content uniformity tests of omeprazole sam-
ples were carried out according to the modified method of
BP 2010 and 2015 [28, 29] or USP 34 and 37 [30, 31] as
indicated in the package insert or on the outer package of
each sample. For the identification test, a chromatogram
of the sample was compared with that of reference stand-
ard omeprazole. The retention time of the principal peak
in the sample chromatograms was similar to that of the
peak of standard omeprazole. Standard solutions were
prepared by dissolving accurately weighed quantities of
omeprazole (reference standard) and lansoprazole (in-
ternal standard) in the diluent to obtain solutions with
concentrations of 0.2 mg/mL and 0.1 mg/mL, respectively.
From these stock solutions, five diluted omeprazole solu-
tions (0.2, 0.15, 0.1, 0.05 and 0.025 mg/mL) were prepared.
The relationship between the peak area and concentration
of each reference standard was linear within the range of
25–200% of the active ingredient (r2 = 0.999–1.000), and
the quality test was performed within that range.
In the quantity test, acceptance criteria of omeprazole
for BP samples were as follows: tablets/capsules contain
the equivalent of not less than 95.0% and not more than
105.0% of the labeled amount of omeprazole. For USP
samples, the acceptance range was between 90–110%.
The acceptance value for the content uniformity test
was ≤ 15. In the dissolution test, the maximum percent-
age of omeprazole allowed to be dissolved in the acid
stage for BP samples was the average of 24 units is not
more than 10% and no individual unit is not more 25%
of omeprazole dissolved. For USP samples, the tolerance
in the acid stage was the average of 24 units is not more
than 20% of omeprazole dissolved, not more than two
units are greater than 35% of omeprazole dissolved and
no individual unit is greater than 45% of omeprazole dis-
solved. In the buffer stage, the acceptance criterion for
BP samples was the average value of 24 units is equal to
or greater than Q (Q = 65%), not more than 2 units are
less than Q-15% & no unit is less than Q-25% (Q = 65)
and for USP samples, criterion was the average value of
24 units is equal to or greater than Q (Q = 75%), not
more than 2 units are less than Q-15% & no unit is less
than Q-25% (Q = 75).
Omeprazole dissolution test and examination of
dissolution profile
The dissolution test was performed according to the BP
or USP as indicated by the sample products. BP Samples
were exposed to 700 mL phosphate buffer, pH 4.5, for
45 min in acid stage and 900 mL phosphate buffer,
pH 6.8 for 45 min in buffer stage [28, 29]. USP samples
were exposed to 500 mL of 0.1 N HCl for 2 h in acid
stage and 900 mL of phosphate buffer, pH 6.8 for
30 min in buffer stage [30, 31]. The dissolution test was
conducted with a NTR-VS 6P dissolution apparatus
(Toyama Sangyo Co. Ltd., Osaka, Japan). Drug release
studies were carried out by paddle method. The paddle
was set to rotate at 100 rpm and the temperature was
maintained at 37 ± 0.5 °C.
To examine the dissolution profile, three capsules were
used. Since all the failed samples were BP samples, in the
investigation with the acid stage, test samples were ex-
posed to 700 mL phosphate buffer, pH 4.5, for 45 min.
After 45 min, a 5 mL aliquot was withdrawn from each
vessel for quantification by HPLC. Then 200 mL of phos-
phate buffer, pH 7.6, was added to adjust the final pH to
6.8 (buffer stage). In this stage, 5 mL aliquots were with-
drawn from each dissolution vessel at 5, 15, 30, 45, and
60 min for quantification by HPLC. In the investigation
without the acid stage, samples were exposed to the buffer
stage directly without the previous acid stage, and samples
were collected in the same manner as described above.
Scanning electron microscopy
Surface morphology of omeprazole granules was character-
ized by means of scanning electron microscopy on a Hitachi
S-3400 instrument equipped with a Hitachi E-1010 ion
sputter device. A few omeprazole granules were removed







Country of manufacturer Quality tests Acceptable Unacceptable Pendinga
Domestic (n/%) Imported (n/%) n/% n/% n/%
Cambodia 2010
(n = 91)
Pharmacy 26/28.5 2/2.2 89/97.8 Quantity 54/59.3 22/24.2 15/16.5
Depot 45/49.5 Content Uniformity 31/34.1 14/15.4 46/50.5
Wholesaler 8/8.8
Outlet 12/13.2 Dissolution 42/46.2 45/49.4 4/4.4
Myanmar 2014
(n = 65)
Pharmacy 35/53.8 0/0 65/100 Quantity 42/64.6 23/35.4 0/0
Hospital 26/40 Content Uniformity 56/86.2 9/13.8 0/0
Wholesaler 4/6.2 Dissolution 48/73.8 17/26.2 0/0
aInsufficient material was available for full testing
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from the capsule shell, mounted on a stub of metal with
adhesive, coated with platinum, and observed.
X-Ray computed tomography
X-Ray CT of the samples was conducted using an
inspeXio SMX-100CT (Shimadzu) equipped with a
sealed tube type micro focus X-ray generator with a
maximum output of 100 kV, and a high-sensitivity image
intensifier. The sample granules were positioned be-
tween the X-ray generator and the X-ray detector, and
X-ray fluoroscopic data was collected from every angle
by rotating the sample through 360°. Finally, computed
tomographic images (CT images) were calculated from
the obtained data.
Fig. 1 Dissolution profiles (percent release) of omeprazole in buffer stage with and without acid stage. a The standard sample; b one failed
omeprazole sample (B-040) from Cambodia; c two failed omeprazole samples from Myanmar. Each value represents mean ± SD of three
capsules except for (b) where n = 1. Significant differences were evaluated (**p < 0.01) comparing percent dissolution of the capsules in
with and without acid stage at each time point using student’s t-test. For the dissolution profile of Cambodian sample only one capsule
was used in each stage, the result of which was not available for statistical comparison
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Fig. 2 HPLC chromatogram of omeprazole samples in acid resistance stage. a Omeprazole reference standard; b standard omeprazole sample;
c passed omeprazole sample; and d failed omeprazole sample
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Statistical Analysis
Statistical analyses were performed using Microsoft
Excel and SPSS 19.0.0 (IBM SPSS Inc. Chicago, IL,
USA). Statistical differences between the experimental
groups were analyzed by Student’s t-test. Statistical sig-
nificance was evaluated at the 5% level.
Results
Quality analysis of collected samples
Among the 156 omeprazole samples collected, 45
(28.8%) were unacceptable in the quantity test, while 23
(14.7%) were unacceptable in the content uniformity
test. In the dissolution test, 90 samples (57.7%) were ac-
ceptable and 62 (39.7%) were unacceptable (Table 1).
Dissolution profile: Effect of the acid stage on drug
release
Figure 1 (a) shows the percent of omeprazole released in
buffer from a standard sample (Losec) with and without
the acid stage; in this case, the enteric coating of the gran-
ules retained its integrity in the acid stage, as expected,
and the percent release of omeprazole without the acid
stage was not much different from the percent release of
omeprazole with the acid stage. Figure 1 (b) and (c) show
the percent of drug released from the omeprazole granules
of one Cambodian sample and two Myanmar samples
respectively. In these cases, the pattern of drug release in
buffer without the acid stage was significantly higher than
that with the acid stage, suggesting that the enteric coating
of the failed samples was not fully effective.
Acid degradation of omeprazole
Typical chromatograms of reference standard omepra-
zole, standard omeprazole, a passed omeprazole sample
and a failed omeprazole sample are shown in Fig. 2. The
failed sample showed peaks indicating that degradation
had occurred.
To confirm this, reference standard (pure) omeprazole
was exposed to acid (pH 4.5) and aliquots were with-
drawn for HPLC analysis at 0, 10, 30, and 45 min. As
shown in Fig. 3, peaks of degradation products increased
time-dependently, and the time course of remaining
omeprazole is shown in Fig. 4. These results are consist-
ent with the conclusion that the failed omeprazole sam-
ples lacked effective enteric coating.
Variability of granules in samples
Considerable variability related to the formulation or
manufacturing process of omeprazole has been sug-
gested in Cambodian samples [6], and we found similar
variation in some Myanmar samples. The shape of the
granules ranged from spherical to irregular, and
different-colored granules were seen, as illustrated in
Fig. 5. We isolated white, yellow, and grey granules, and
Fig. 3 Chromatograms of pure omeprazole in acid at different time
points. a 0 min; b 15 min; c 30 min; and d 45 min
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quantified them individually. The omeprazole contents
in the white, grey and yellow granules were 64.1 ± 0.2,
61.4 ± 0.5 and 42.7 ± 1.7 mg (mean ± SD) per 267.8 mg
of granules (average weight of six granules).
Examination of granules by scanning electron microscopy
Representative SEM images are shown in Fig. 6. Com-
pared with the standard sample (a), granules from failed
omeprazole samples collected in Cambodia in 2010
showed cracks in the enteric coating, along with the
broken pellets. These were mixed with the regular
granules in the capsule.
Examination of granules by X-ray computed tomography
To confirm the absence of functional enteric coating, we
performed X-ray CT on selected samples that failed
severely in the dissolution test and conducted a com-
parative study of the standard sample and failed samples.
Fig. 4 Time course of degradation of pure omeprazole in acid
Fig. 5 Difference in the color of granules in a capsule (sample A-078). a Mixed granules found after opening the capsule shells; b separated white
granules; c grey granules; and d yellow granules
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Figure 7 shows two different granules taken from the
same capsule in a sample collected in Cambodia in
2010. One granule shows an apparently intact coating
(Fig. 7a), while the other (Fig. 7b) has essentially no
coating at all. Similar results were seen in failed samples
from Myanmar, which contained non-uniform granules,
incomplete granules, and granules with holes. Figure 8
shows representative X-ray CT images of granules from
a failed Myanmar sample.
Discussion
Our findings for samples collected in Myanmar in 2014
indicate that the incidence and condition of substandard
omeprazole medicines in Myanmar are quite similar to
those in Cambodia. Yoshida et al. found that 45 out of
91 omeprazole samples collected in Cambodia in 2010
(49.5%) were unacceptable in the dissolution test
(Table 1) [6]. Among the Myanmar samples, 23 (35.4%)
failed the quantity test, although the extent of failure
was generally marginal. A few failed due to over-content.
Moreover, significant differences were observed in the
quality test, where some brands passed in most cases,
while others were consistently substandard. It was par-
ticularly noteworthy that the products of certain manu-
facturers failed consistently.
In the present work, our prime concern was the
failures in dissolution tests. Among the 17 (26.2%)
unacceptable samples from Myanmar, all failed in the
buffer stage and 11 failed in both the acid and buffer
stages. A key issue appeared to be that the coating of
the granules did not provide good control of the drug
release, so that rapid disintegration and dissolution
Fig. 6 SEM images of cracked and fractured pellets found in two representative Cambodian samples. a Standard sample; b and c two different
granules of sample A-063; and d Sample A-108
Fig. 7 X-Ray CT images of granules found in sample B-040 collected in Cambodia in 2010. Note the presence of an apparently intact enteric-
coated layer in (a) and the absence of an enteric-coated layer in (b)
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occurred in the acid stage of the test, resulting in exposure
of omeprazole to acid degradation [17, 19, 32, 33]. In-
deed, an HPLC analysis showed that degradation of
omeprazole in the granules of failed samples during
the acid stage was similar to that of pure omeprazole
(Fig. 3), confirming that the enteric coating was
ineffective.
This conclusion was further supported by SEM images
(Fig. 6), which revealed fractured pellets and pellets with
incomplete coating, together with pellets with apparently
intact coating. Macroscopically, a sample from Cambodia
contained two different types of granules in a single
capsule, and the X-ray CT images showed that one
type of granule lacked enteric coating (Fig. 7). Similar
results were found in a sample from Myanmar, which
appeared to contain three different types of granules
(Fig. 5). The X-ray CT images revealed that the coat-
ing of some granules was incomplete and some gran-
ules contained holes (Fig. 8). Thus, there was marked
inconsistency among omeprazole granules in capsules,
and this suggests that at least some manufacturers
were using inadequate enteric coating technology or
conditions. However, we were unable to confirm this
with the manufacturers. Substandard medicines are a
serious public health issue. In the case of omeprazole,
substandard samples without enteric coating or with
incomplete enteric coating will degrade rapidly in the
acidic environment of the stomach after oral adminis-
tration, and this may result in treatment failure.
It should be noted that in some cases the size of our
samples was insufficient for detailed examination, and
this represents a weakness of our study, in that we could
not fully assess the actual extent of quality failure in
our analysis. Another limitation is that; we could not
confirm the coating material used during the manufac-
ture of the enteric coated pellets or if there was
inadequate coating method (e.g. inadequate equipment
or inadequate coating parameters) as the response to
the questionnaire from the manufacturers was mini-
mum. Therefore, further investigation is needed to
establish precisely the scale of the problem of substand-
ard medicines in Myanmar and Cambodia. In addition,
action, including regulatory measures, should be initi-
ated to prevent the manufacture and sale of substand-
ard medicines.
Conclusions
Samples of omeprazole capsules collected in Cambodia
in 2010 and Myanmar in 2014 showed high failure rates
in pharmacopoeial testing, especially in the dissolution
test. In-vitro dissolution profiling, scanning electron mi-
croscopy and X-ray computed tomography showed that
failed samples contained granules with ineffective
(cracked or incomplete) or absent enteric coating. This
Fig. 8 X-Ray CT images of granules found in sample A-078 collected in Myanmar in 2014. a Standard sample; b regular granule with apparently
intact coating (white granule 1); c irregular granule with hole (white granule 2); and d yellow granule with incomplete coating
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would result in premature dissolution in acidic con-
ditions after oral administration, and could result in
treatment failure. This situation is a potentially serious
public health issue that needs to be addressed by regula-
tory authorities in Cambodia and Myanmar, possibly
through legal measures and collaborative initiatives with
manufacturers.
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